Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tetsu Hayashida

Showing results (31-40 of 84) with videos related to

Pageof 9
Sort By:
Cancer Science|March 13, 2022
Feasibility study on collecting patient-reported outcomes from breast cancer patients using the LINE-ePRO systemTetsu Hayashida, Aiko Nagayama, Tomoko Seki, et al.
Annals of Surgical Oncology|March 8, 2012
HOXB9 expression promoting tumor cell proliferation and angiogenesis is associated with clinical outcomes in breast cancer patientsHirohito Seki, Tetsu Hayashida, Hiromitsu Jinno, et al.
Cancer Science|April 14, 2010
Overexpression of leucine-rich repeat-containing G protein-coupled receptor 5 in colorectal cancerHiroshi Uchida, Ken Yamazaki, Mariko Fukuma, et al.
Oncology Letters|March 15, 2019
Experimental and clinicopathological analysis of HOXB9 in gastric cancerFumihiko Kato, Norihito Wada, Tetsu Hayashida, et al.
Japanese Journal of Clinical Oncology|October 22, 2015
Biological markers of invasive breast cancerAkiko Matsumoto, Hiromitsu Jinno, Tomofumi Ando, et al.
International Journal of Clinical Oncology|February 28, 2019
Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patientsRurina Watanuki, Tetsu Hayashida, Yuko Kawai, et al.
Breast Cancer Research and Treatment|January 18, 2021
Comprehensive analysis of the homeobox family genes in breast cancer demonstrates their similar roles in cancer and developmentAyako Nakashoji, Tetsu Hayashida, Shigeo Yamaguchi, et al.
The Oncologist|June 1, 2024
Phase II clinical trial of docetaxel and trastuzumab for HER2-positive advanced extramammary Paget's disease (EMPD-HER2DOC)Ikuko Hirai, Keiji Tanese, Yoshio Nakamura, et al.
Oncology Reports|March 15, 2014
Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancerYuki Seo, Yoshiyuki Ishii, Hiroki Ochiai, et al.
The Breast Journal|May 26, 2020
Impact of neoadjuvant and adjuvant chemotherapy on invasive lobular carcinoma: A propensity score-matched analysis of SEER dataRurina Watanuki, Tetsu Hayashida, Takamichi Yokoe, et al.
Pageof 9

Showing results (31-40 of 84) with videos related to

Sort By:
Pageof 9
Cancer Science|March 13, 2022
Feasibility study on collecting patient-reported outcomes from breast cancer patients using the LINE-ePRO systemTetsu Hayashida, Aiko Nagayama, Tomoko Seki, et al.
Annals of Surgical Oncology|March 8, 2012
HOXB9 expression promoting tumor cell proliferation and angiogenesis is associated with clinical outcomes in breast cancer patientsHirohito Seki, Tetsu Hayashida, Hiromitsu Jinno, et al.
Cancer Science|April 14, 2010
Overexpression of leucine-rich repeat-containing G protein-coupled receptor 5 in colorectal cancerHiroshi Uchida, Ken Yamazaki, Mariko Fukuma, et al.
Oncology Letters|March 15, 2019
Experimental and clinicopathological analysis of HOXB9 in gastric cancerFumihiko Kato, Norihito Wada, Tetsu Hayashida, et al.
Japanese Journal of Clinical Oncology|October 22, 2015
Biological markers of invasive breast cancerAkiko Matsumoto, Hiromitsu Jinno, Tomofumi Ando, et al.
International Journal of Clinical Oncology|February 28, 2019
Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patientsRurina Watanuki, Tetsu Hayashida, Yuko Kawai, et al.
Breast Cancer Research and Treatment|January 18, 2021
Comprehensive analysis of the homeobox family genes in breast cancer demonstrates their similar roles in cancer and developmentAyako Nakashoji, Tetsu Hayashida, Shigeo Yamaguchi, et al.
The Oncologist|June 1, 2024
Phase II clinical trial of docetaxel and trastuzumab for HER2-positive advanced extramammary Paget's disease (EMPD-HER2DOC)Ikuko Hirai, Keiji Tanese, Yoshio Nakamura, et al.
Oncology Reports|March 15, 2014
Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancerYuki Seo, Yoshiyuki Ishii, Hiroki Ochiai, et al.
The Breast Journal|May 26, 2020
Impact of neoadjuvant and adjuvant chemotherapy on invasive lobular carcinoma: A propensity score-matched analysis of SEER dataRurina Watanuki, Tetsu Hayashida, Takamichi Yokoe, et al.
Pageof 9